Arrowhead Pharmaceuticals, Inc. ARWR 深 沪
交易中 11-13 10:35:00 美东时间
46.465
-0.685
-1.45%
华盛通- 最 高48.29
- 今 开47.68
- 成交量 77.69万股
- 最 低 44.52
- 昨 收 47.15
- 总市值 65.63亿
- 52周最高 95.4899
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 40.43
- 委 比 -33.33%
- 总股本 1.41亿
- 历史最高 95.4899
- 量 比 1.85
- 振 幅 8.00%
- 历史最低 1.22
- 每 手 1
- 风险率 11.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stifel Maintains Buy on Arrowhead Pharma, Lowers Price Target to $96
Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.
今天 20:50
Arrowhead Pharma Q4 EPS $(3.01) Misses $(1.61) Estimate, Sales $37.794M Miss $55.838M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(3.01) per share which missed the analyst consensus estimate of $(1.61) by 86.96 percent. This is a 1572.22 percent decrease over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $37.794 m...
今天 05:28
财报速睇 | Arrowhead Pharmaceuticals, Inc. 2026财年年度营收4.51亿美元，同比下降45.6%；归母净利润亏损7.24亿美元，同比亏损扩大44302.6%
华盛资讯11月13日讯，Arrowhead Pharmaceuticals, Inc.公布2026财年年度业绩，公司年度营收4.51亿美元，同比下降45.6%，归母净利润亏损7.24亿美元，同比亏损扩大44302.6%。
今天 05:19
财报速睇 | Arrowhead Pharmaceuticals, Inc. 2026财年年度营收4.51亿美元，同比下降45.6%；归母净利润亏损7.24亿美元，同比亏损扩大44302.6%
华盛资讯11月13日讯，Arrowhead Pharmaceuticals, Inc.公布2026财年年度业绩，公司年度营收4.51亿美元，同比下降45.6%，归母净利润亏损7.24亿美元，同比亏损扩大44302.6%。
今天 05:16
Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test
Cisco Systems and Applied Materials headline Thursday’s reports, with investors looking for evidence that AI infrastructure demand can keep supporting semiconductor and networking growth. Brookfield, Nebius Group, Ascendis Pharma, Hudbay Minerals and Twist Bioscience report before the open; Cisco Sy...
11-12 04:30
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Biotech ETFs face a pivotal week as Summit Therapeutics (NASDAQ:SMMT) approaches a key FDA decision, while fresh drug-development updates and Hims & Hers Health Inc (NYSE:HIMS) partnership with Eli Lilly And Co (NYSE:LLY) put healthcare’s growth prospects in focus. Healthcare stocks have shown resil...
11-10 00:51
Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with Familial Chylomicronaemia Syndrome (FCS) diagnosed via genetic testing or clinical criteria1 The...
10-27 23:40
美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on Day 105, with a maximum individual reduction of 85%, supporting the potential f...
10-14 19:32
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
